Blood, Whole

Summary

Blood, Whole (CHEMBL2108414) is a phase-3 clinical-stage unknown targeting KCNC4; indicated across 5 conditions including injury and infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Targets: 1 (KCNC4)
• Indications: 5 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108414
Name	Blood, Whole
Type	Unknown
Max phase	3

Also known as: Blood, whole, Whole blood, BLOOD, WHOLE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
KCNC4	Kv3.4		7.3	4.4%	Q03721

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): KCNC4.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Neuronal System	1	KCNC4
Potassium Channels	1	KCNC4
Voltage gated Potassium channels	1	KCNC4

Dominant GO biological processes

GO term	Targets
action potential	1
potassium ion transport	1
chemical synaptic transmission	1
protein homooligomerization	1
potassium ion transmembrane transport	1
monoatomic ion transport	1
monoatomic ion transmembrane transport	1
transmembrane transport	1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
injury	3	MONDO:0021178	EFO:0000546
infectious disease	3	MONDO:0005550	EFO:0005741
brain injury	3	MONDO:0043510	MONDO:0043510
anemia	2	MONDO:0002280	EFO:0004272

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
Not specified	9
PHASE3	2
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02978833	PHASE4	TERMINATED	Platelet-rich Plasma vs. Whole Blood for Gluteus Medius Tendinopathy
NCT03477006	PHASE3	TERMINATED	Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial
NCT04704869	PHASE3	COMPLETED	Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
NCT01461590	PHASE2	COMPLETED	Study of Safe Blood Transfusion Volumes to Correct Acute Severe Anaemia
NCT03981484	PHASE2	UNKNOWN	REPlaCE- Randomized Trial Evaluating the Use of Prothrombin Complex concEntrate to Improve Survival in Patients With Traumatic Coagulopathy
NCT04278404	Not specified	RECRUITING	Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT06495294	Not specified	RECRUITING	SWiFT Canada (Study of Whole Blood in Frontline Trauma)
NCT00582868	Not specified	TERMINATED	Use of Brain Oxygen Tension Level and Cleaved-tau Protein to Detect Vasospasm After SAH
NCT01946750	Not specified	COMPLETED	Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections
NCT02216019	Not specified	COMPLETED	Diagnostic Interest of Leukocyte Immunophenotyping Using Multiparameter 8-color Flow Cytometry in Heart Surgery
NCT02797743	Not specified	UNKNOWN	Whole Blood Specimen Collection From Healthy Subjects
NCT03228095	Not specified	UNKNOWN	Volatiles in Breath and Headspace Analysis - Diagnostic Markers
NCT05691621	Not specified	UNKNOWN	Galectin-3 in Septic and Non-septic Acute Kidney Injury
NCT05955079	Not specified	UNKNOWN	Circulating Tumor DNA Study in Patients With Endometrial Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).